Solasia Pharma K.K.
4597・Growth Market・Pharmaceuticals
Business
Solasia Pharma is a specialty pharma company that in-licenses promising new drug candidates from overseas pharmaceutical companies and biotech ventures, conducts clinical development and regulatory approval in Japan and Asian countries centered on China and Korea, and monetizes them through out-licensing or its own sales. It currently markets three products: oncology treatments (Sancuso® and Darvias®) and an oncology supportive care medical device (Episil®). It also holds a development pipeline including SP-04 (peripheral neuropathy), SP-05 (antitumor effect enhancement), and RECQL1-siRNA (a nucleic acid drug candidate), while outsourcing manufacturing and basic research and concentrating management resources on clinical development functions. The company listed on the Tokyo Stock Exchange Mothers market (now Growth Market) in 2017.
Business Model
The company holds no manufacturing or basic research functions of its own, specializing instead in clinical development capabilities. It in-licenses drug candidates, enhances their value through clinical trials, and out-licenses exclusive sales rights to regional distribution partners, thereby earning upfront license fees, development milestones, sales milestones, royalties, and product supply revenue. Currently, sales revenue from three products constitutes the main revenue source, supplemented by out-licensing revenue (such as rights to Episil® in Brazil). The company remains in a phase of upfront investment, supporting its operations through continuous fundraising (including exercise of stock acquisition rights).
Company Strengths
The company has secured sales partners across multiple regions: Sancuso® (China – Lee's Pharmaceutical, and MAAB from 2027 onward), Darvias® (Japan – Nippon Kayaku), and Episil® (Japan – Meiji Seika Pharma, China – Gensci, Brazil – a Daiichi Sankyo subsidiary). Revenue for the fiscal year reached ¥429 million, up 35.4% year on year.
Selling, general and administrative expenses were reduced by ¥1,084 million, from ¥1,721 million in the previous fiscal year to ¥637 million in the current fiscal year (primarily due to a decrease in impairment losses from ¥1,154 million to ¥37 million). Operating loss improved by ¥1,090 million, from ¥1,951 million in the previous fiscal year to ¥861 million in the current fiscal year, making the loss reduction trend clear.
During the fiscal year, the company raised ¥1,458 million in proceeds from share issuance through the exercise of subscription rights, increasing cash and cash equivalents at fiscal year-end to ¥1,387 million. Cash flow from financing activities was positive at ¥1,425 million, securing the funds on hand necessary to continue development.
ENVALITH's Perspective
Performance Trend
Revenue over the past five fiscal periods moved irregularly: ¥559 million → ¥1,092 million → ¥617 million → ¥316 million → ¥429 million, and in Q1 FY2026 (ending December 2026) it fell sharply to ¥6 million (versus ¥25 million in the same period last year). Operating loss narrowed significantly from ¥1,951 million in FY2024 (ended December 2024) to ¥861 million in FY2025 (ended December 2025), but in Q1 FY2026 the loss was ¥306 million (versus ¥296 million in the same period last year), a slight deterioration year-on-year. On the cost side, R&D expenses rose to ¥112 million (versus ¥111 million in the same period last year) and SG&A expenses rose to ¥198 million (versus ¥191 million), both showing an upward trend. Notably, personnel expenses increased by ¥52 million, from ¥104 million to ¥156 million. As an external factor, foreign exchange effects (translation adjustments for foreign operations) are also reflected in comprehensive income, contributing a positive ¥7 million in the current Q1. Operating cash flow deteriorated sharply to a negative ¥63 million, down from a positive ¥211 million in the same period last year, with the shortfall continuing to be offset by financing activities (new share issuance of ¥260 million).
Growth Strategy
Enhance corporate value through regional expansion and completion of partner transition for the three existing products, together with the transition of SP-05 to Phase II
A license agreement was concluded with MAAB in January 2026, under which manufacturing rights were also granted with the intention of local production in China. Both companies are working jointly to complete the sales structure transition as early as possible ahead of the expiration of the contract term with Lee's at the end of 2026. Installment contract fee income will be disclosed as it is confirmed.
Gensci began sales in China from March 2025, recognizing ¥6 million in product sales revenue in the first quarter under review. In Brazil, an exclusive sales rights license agreement was concluded with Daiichi Sankyo Brasil (a wholly owned subsidiary of Daiichi Sankyo) in August 2025. Sales expansion in both regions is a key component of the estimated ¥420 million in product sales revenue for the full fiscal year 2026.
Tumor shrinkage was confirmed in all patients evaluated in the Phase Ib/II trial conducted in Germany. The third cohort is currently underway, and based on the results of the Phase Ib portion, a Phase II trial in Japan is planned to begin in the latter half of FY2026. Investment in Isofol (cumulative total of ¥111 million) is being used to strengthen development collaboration. R&D expenses for FY2026 are expected to be ¥700 million.
In addition to relapsed/refractory peripheral T-cell lymphoma, in vitro non-clinical studies are underway at domestic universities and Chinese research institutions to explore expansion into other cancer types. In the 13 countries of Eastern Europe, an exclusive sales rights license agreement premised on the MAP (Managed Access Program) framework was concluded with INTEGRIS PHARMA in August 2025. Activities to out-license rights in China are also ongoing.
Last updated: July 17, 2026